479 related articles for article (PubMed ID: 15684150)
1. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K
Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
[TBL] [Abstract][Full Text] [Related]
2. Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
Mason MV; Poole-Yaeger A; Krueger CR; House KM; Lucas B
Manag Care; 2010 Feb; 19(2):46-52. PubMed ID: 20550052
[TBL] [Abstract][Full Text] [Related]
3. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
Joy S; Rhea DJ; Istwan NB; Desch CN; Stanziano G
Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
[TBL] [Abstract][Full Text] [Related]
4. 17 hydroxyprogesterone for the prevention of preterm delivery.
Meis PJ;
Obstet Gynecol; 2005 May; 105(5 Pt 1):1128-35. PubMed ID: 15863556
[TBL] [Abstract][Full Text] [Related]
5. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
González-Quintero VH; Istwan NB; Rhea DJ; Smarkusky L; Hoffman MC; Stanziano GJ
J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
[TBL] [Abstract][Full Text] [Related]
6. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate.
Rebarber A; Ferrara LA; Hanley ML; Istwan NB; Rhea DJ; Stanziano GJ; Saltzman DH
Am J Obstet Gynecol; 2007 Mar; 196(3):224.e1-4. PubMed ID: 17346529
[TBL] [Abstract][Full Text] [Related]
7. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
8. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Merlob P; Stahl B; Klinger G
Reprod Toxicol; 2012 Jan; 33(1):15-9. PubMed ID: 22120850
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting.
Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
Am J Obstet Gynecol; 2007 Sep; 197(3):262.e1-4. PubMed ID: 17826412
[TBL] [Abstract][Full Text] [Related]
10. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery.
Rebarber A; Istwan NB; Russo-Stieglitz K; Cleary-Goldman J; Rhea DJ; Stanziano GJ; Saltzman DH
Diabetes Care; 2007 Sep; 30(9):2277-80. PubMed ID: 17563346
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
Sibai BM; Istwan NB; Palmer B; Stanziano GJ
Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
[TBL] [Abstract][Full Text] [Related]
12. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
[TBL] [Abstract][Full Text] [Related]
13. 17-α hydroxyprogesterone caproate for the prevention of preterm birth.
Gupta S; Roman AS
Womens Health (Lond); 2012 Jan; 8(1):21-30. PubMed ID: 22171770
[TBL] [Abstract][Full Text] [Related]
14. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
Coleman S; Wallace L; Alexander J; Istwan N
J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
[TBL] [Abstract][Full Text] [Related]
15. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
Spong CY; Meis PJ; Thom EA; Sibai B; Dombrowski MP; Moawad AH; Hauth JC; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S;
Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1127-31. PubMed ID: 16157124
[TBL] [Abstract][Full Text] [Related]
16. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
Ventolini G; Duke J; Po W; Barhan S; Rhea D; Desch C; Istwan N; Stanziano G
J Reprod Med; 2008 Sep; 53(9):667-71. PubMed ID: 18839818
[TBL] [Abstract][Full Text] [Related]
17. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Rozenberg P; Chauveaud A; Deruelle P; Capelle M; Winer N; Desbrière R; Perrotin F; Bohec C; Connan L; Vayssière C; Langer B; Mantel A; Azimi S; Porcher R; Azria E;
Am J Obstet Gynecol; 2012 Mar; 206(3):206.e1-9. PubMed ID: 22381603
[TBL] [Abstract][Full Text] [Related]
18. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
How HY; Barton JR; Istwan NB; Rhea DJ; Stanziano GJ
Am J Obstet Gynecol; 2007 Sep; 197(3):260.e1-4. PubMed ID: 17826411
[TBL] [Abstract][Full Text] [Related]
20. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
Rebarber A; Cleary-Goldman J; Istwan NB; Rhea DJ; Desch C; Russo-Stieglitz K; Saltzman DH
Am J Perinatol; 2008 May; 25(5):271-5. PubMed ID: 18401840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]